英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
gessen查看　gessen　在百度字典中的解释百度英翻中〔查看〕
gessen查看　gessen　在Google字典中的解释Google英翻中〔查看〕
gessen查看　gessen　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • RINVOQ - accessdata. fda. gov
    RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers If TNF
  • U. S. Food and Drug Administration (FDA) Approves Updated Indication . . .
    This label update gives healthcare providers the option to prescribe RINVOQ for patients with moderately to severely active inflammatory bowel disease after the use of one approved systemic therapy if TNF blockers are deemed clinically inadvisable by the prescribing physician "
  • RINVOQ® (upadacitinib) - Official Healthcare Professional Site
    Learn about RINVOQ® (upadacitinib), approved for RA, PsA, AS, nr-axSpA, pJIA, GCA, AD, UC, and CD See full Prescribing Information and Important Safety Information, including BOXED WARNING
  • RINVOQ- upadacitinib tablet, extended release - fda. report
    RINVOQ initiation is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells mm 3, absolute neutrophil count (ANC) less than 1000 cells mm 3, or hemoglobin level less than 8 g dL [see Warnings and Precautions (5 4)]
  • RINVOQ® (upadacitinib) for RA, PsA, AD, AS, nr-axSpA, UC, CD, pJIA JPsA
    RINVOQ RINVOQ LQ is approved in children 2+ years with active pJIA and in children 2 to less than 18 years with active psoriatic arthritis when TNF blockers did not work well or could not be tolerated RINVOQ LQ is not the same as RINVOQ tablets Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your healthcare provider
  • Upadacitinib (RINVOQ) in Giant Cell Arteritis
    Antiviral prophylaxis for HBV: Agents with high genetic barrier to resistance such as entecavir or tenofovir should be used When possible, vaccinations should be updated before the patient initiates upadacitinib
  • FDA Label for Rinvoq Tablet, Extended Release Oral - NDC List
    RINVOQ ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate
  • Upadacitinib Monograph for Professionals - Drugs. com
    Measure absolute lymphocyte count, absolute neutrophil count (ANC), and hemoglobin Do not initiate therapy in patients with an absolute lymphocyte count of <500 cells mm 3, ANC <1000 cells mm 3, or hemoglobin concentration <8 g dL
  • RINVOQ RINVOQ LQ® (upadacitinib) - The Agency for Health Care . . .
    Rinvoq will not be used in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants; AND Patient individual risks and benefits have been considered prior to initiating or continuing therapy in those at higher risk for malignancy and or major adverse cardiovascular events (MACE); AND
  • U. S. Food and Drug Administration (FDA) Approves Updated . . . - BioSpace
    This label update gives healthcare providers the option to prescribe RINVOQ for patients with moderately to severely active inflammatory bowel disease after the use of one approved systemic therapy if TNF blockers are deemed clinically inadvisable by the prescribing physician "





中文字典-英文字典  2005-2009